Tag: Sorrento
Sorrento Posts Form 8937 to Supplement its Previously Issued “FAQ” Regarding...
SAN DIEGO, Feb. 18, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. SRNE "Sorrento"))) today posted an IRS Form 8937 (the "Form...
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, In… –...
PALO ALTO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary...
Sorrento Announces Positive Results From Its License Partner, Kelun, on a...
A166 (ASCO Abstract #1024) is a third generation antibody drug conjugate (ADC) against HER2-positive breast cancer with Levena’s proprietary tubulin inhibitor Duo-5 toxin,...
Sorrento Announces Updated Positive Results of Phase 1b Study of COVI-MSC™...
All nine patients with acute respiratory failure due to COVID-19 discharged from hospital within days after 3rd COVI-MSC infusionPreparations are ongoing for initiating...
Lee’s Pharmaceutical Announces its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics,...
Socazolimab is an anti-PD-L1 antibody licensed from Sorrento for the Greater China Territory by Lee’s Pharm.China’s National Medical Products Administration (“NMPA”) clears Lee’s...